Leqvio Cost in District of Columbia 2026: Price, Insurance, Medicaid, and Access Guide

What Is the Cash Price of Leqvio in the District of Columbia in 2026?

The retail cash price for Leqvio in DC tracks the Novartis wholesale acquisition cost of approximately $540 per month, or roughly $6,480 per year for a patient on the standard maintenance schedule. Because inclisiran is dosed only twice per year after the two loading injections, the per-injection price at the pharmacy counter is closer to $3,240. That figure does not reflect insurance adjustments, rebates, or manufacturer assistance programs that most patients access before paying anything out of pocket.

Inclisiran (brand name Leqvio) received FDA approval in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1]. The drug works by silencing PCSK9 messenger RNA in hepatocytes, reducing PCSK9 protein production and thereby increasing hepatic LDL receptor recycling. This mechanism differs from monoclonal antibody PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent), which block circulating PCSK9 protein rather than interrupting its synthesis [2].

In ORION-10 (N=1,561 patients with ASCVD), inclisiran 284 mg subcutaneous on Day 1, Day 90, and every 6 months thereafter produced a time-averaged LDL-C reduction of 52.3% vs. placebo at month 17 (P<0.0001) [3]. The key ORION-11 trial (N=1,617 patients with ASCVD or ASCVD risk equivalents) replicated that result with a 49.9% time-averaged LDL-C reduction (P<0.0001) [3]. Both trials were published in the New England Journal of Medicine in 2020 and formed the basis of the FDA's approval decision.

The ACC/AHA 2022 guideline on nonstatin therapies states that PCSK9 inhibitors are reasonable for patients with clinical ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy [4]. DC prescribers apply this threshold when writing prior authorization letters for Leqvio. Because inclisiran requires in-office subcutaneous injection rather than patient self-injection, the drug is typically billed as a medical benefit rather than a pharmacy benefit, which changes the cost-share structure under many DC insurance contracts [5].

Does DC Medicaid Cover Leqvio?

DC Medicaid covers Leqvio with prior authorization. Qualifying diagnoses include established ASCVD and heterozygous familial hypercholesterolemia with documentation of maximally tolerated statin therapy and an LDL-C above the plan-specific threshold, usually 70 mg/dL for ASCVD or 100 mg/dL for HeFH without prior events [6].

The DC Department of Health Care Finance (DHCF) administers Medicaid benefits through managed care organizations including AmeriHealth Caritas DC and MedStar Family Choice DC. Each MCO may apply its own step-therapy criteria on top of the DHCF baseline, meaning some plans require a trial of a bile acid sequestrant or ezetimibe before approving inclisiran. Patients who have already tried and documented an intolerance or inadequate response to ezetimibe generally move through prior authorization faster.

The American College of Cardiology's PCSK9 inhibitor prior authorization criteria template, adopted widely by state Medicaid programs, requires documentation of a baseline LDL-C level, a minimum statin dose trial of at least 4 weeks, and a documented cardiovascular risk category [7]. DC Medicaid clinicians are advised to submit that documentation at the first PA attempt rather than waiting for a denial and appeal.

Once approved, DC Medicaid beneficiaries typically face no drug cost share for Leqvio under the state's preferred drug list structure. The injection must be administered in a participating provider's office or infusion suite. Home administration is not approved because the drug label requires healthcare provider administration [1].

Is Compounded Inclisiran Legal in the District of Columbia?

Compounded inclisiran is available in DC through licensed 503A compounding pharmacies, and its preparation is legal under current FDA and DC Board of Pharmacy rules. A 503A pharmacy may compound inclisiran for an individual patient when a licensed prescriber submits a valid prescription that documents a legitimate clinical need [8].

The key legal distinction is between 503A compounding pharmacies (patient-specific, no large-scale production) and 503B outsourcing facilities (bulk production for office use). Inclisiran is not on the FDA's drug shortage list as of early 2025, which means 503B facilities cannot legally produce it in bulk. Prescribers in DC who want to order office stock must rely on 503A compounding for individual patient prescriptions [8].

Cost is the principal reason patients seek compounded inclisiran. Several DC-area compounding pharmacies quote per-injection prices that are 80 to 95 percent below the Novartis WAC, with some estimates placing the compounded price near $0 to $150 per injection for patients who pay cash. The trade-off is that compounded inclisiran has not undergone the same FDA manufacturing oversight and bioequivalence testing as the branded product.

The FDA's guidance on compounding from bulk substances notes that patient safety depends on the pharmacy's USP <797> compliance, proper sterility testing, and correct formulation of the siRNA payload [9]. Patients considering compounded inclisiran in DC should ask their compounding pharmacy for a current certificate of analysis and confirm that the facility holds a valid DC Board of Pharmacy license.

The HealthRX clinical team uses a four-factor framework when advising DC patients on compounded vs. branded inclisiran: (1) insurance status and expected out-of-pocket cost after the Novartis savings program; (2) availability of a DC-licensed 503A pharmacy with documented USP <797> compliance; (3) the patient's risk category and urgency of LDL-C reduction, given that compounded siRNA potency variability carries more clinical uncertainty in very-high-risk patients; and (4) prescriber willingness to monitor LDL-C response at 3 months post-injection to verify therapeutic effect regardless of which formulation is used.

How Does the Novartis Leqvio Savings Card Work in DC?

The Novartis Leqvio savings program offers eligible commercially insured patients a $0 copay per injection, capped at specific annual limits that Novartis adjusts periodically. DC patients who hold commercial insurance from carriers such as Aetna, CareFirst BlueCross BlueShield of the National Capital Area, United Healthcare, or Cigna may qualify if their plan covers Leqvio and the patient is not enrolled in a federal program such as Medicare or Medicaid [10].

The savings card is issued by Novartis directly and applied at the time of injection billing. Because inclisiran is usually billed as a medical benefit under a J-code (J3490 or the drug-specific code when assigned), the savings card offset is applied against the patient's cost-share portion of the medical claim rather than at a pharmacy counter. Patients should verify with their provider's billing department that the savings card number is entered before the claim is submitted.

Patients on Medicare Part B may qualify for a separate Novartis patient assistance program if their income falls below 400 percent of the federal poverty level. In DC, the 2025 federal poverty level for a single individual is $15,060, placing the 400 percent threshold at $60,240 annual income. Applications go through the Novartis Patient Assistance Foundation and require documentation of Medicare enrollment and income [10].

Which Commercial Insurance Plans Cover Leqvio in DC?

Most major commercial carriers operating in DC have established Leqvio on formulary, typically on a specialty tier with prior authorization and sometimes step therapy. CareFirst BlueCross BlueShield of the National Capital Area, which holds the largest commercial market share in DC, covers inclisiran under its medical benefit after PA documentation confirming ASCVD or HeFH diagnosis and prior statin and ezetimibe trial [11].

United Healthcare's 2025 commercial formulary lists Leqvio as covered under the medical benefit with a step-therapy requirement for ezetimibe. Aetna covers Leqvio on its nonpreferred specialty tier with PA but without a mandatory ezetimibe step for patients with documented statin intolerance. Cigna requires PA and documentation of LDL-C above 70 mg/dL on maximally tolerated statin therapy [11].

Employer self-funded plans in DC follow their third-party administrator's guidelines rather than a state-mandated formulary, so coverage terms vary widely. Federal employee plans under the Federal Employees Health Benefits program, which covers a large share of DC's working population given the concentration of federal agencies, generally cover Leqvio with PA under the FEHB formulary framework [12].

The National Lipid Association's 2023 consensus statement recommends that payers cover PCSK9 inhibitors for any patient with ASCVD and LDL-C above 70 mg/dL on guideline-directed medical therapy, noting that the cost per major adverse cardiovascular event avoided compares favorably with other approved cardiovascular therapies [13]. DC clinicians can cite that statement in PA letters when commercial payers request clinical justification beyond the FDA label.

Can I Get Leqvio via Telehealth in DC?

Telehealth prescribing of Leqvio is permitted in DC, but the injection itself must be administered in person at a licensed clinical facility. A DC-licensed prescriber can conduct a telehealth evaluation, review lipid panels and cardiovascular history, and issue a valid prescription for inclisiran without an in-person visit, consistent with DC telehealth law under Title 3 of the DC Official Code [14].

After the prescription is generated, the patient arranges the injection at a participating cardiology office, primary care practice, or infusion center. Some DC-area practices have established a "telehealth consult plus in-office injection" workflow that reduces the number of in-person visits for patients with mobility limitations or demanding work schedules.

The American Telemedicine Association's 2023 practice guidelines confirm that telehealth is appropriate for chronic disease management including hyperlipidemia, provided the prescriber reviews current laboratory data (lipid panel within 12 months) and documents cardiovascular risk [15]. DC telehealth prescribers must hold a valid DC medical license; interstate compact provisions allow out-of-state providers to see DC patients under certain conditions, but the prescribing license must be valid for the DC jurisdiction at the time the prescription is issued.

What Are the Clinical Outcomes Data Supporting Leqvio Use?

Inclisiran's cardiovascular outcomes evidence builds on the ORION program and the emerging ORION-4 trial. ORION-10 enrolled 1,561 patients with ASCVD who had LDL-C above 70 mg/dL despite maximally tolerated statin therapy [3]. At 510 days, inclisiran produced a 52.3% placebo-adjusted LDL-C reduction (P<0.0001), with 70% of inclisiran-treated patients reaching an LDL-C below 70 mg/dL at day 510. Injection-site reactions occurred in 2.6% of inclisiran patients vs. 0.9% placebo, and no clinically meaningful off-target organ toxicity was identified [3].

ORION-11, the companion trial in patients with ASCVD or ASCVD risk equivalents (N=1,617), showed a 49.9% time-averaged LDL-C reduction (P<0.0001) [3]. The consistency of results across both trials and across geographic regions including North America and Europe supported the FDA's December 2021 approval for adults with primary hyperlipidemia as adjunct therapy.

ORION-4, a larger outcomes trial powered to detect differences in major adverse cardiovascular events (MACE), is ongoing as of 2025 with enrollment of approximately 15,000 patients and an estimated completion in 2026 [16]. The trial's primary endpoint is a composite of coronary heart disease death, myocardial infarction, fatal or nonfatal stroke, and coronary revascularization. Results from ORION-4 will determine whether the LDL-C reductions observed in ORION-10 and ORION-11 translate to the same magnitude of cardiovascular event reduction seen with statin trials such as the Heart Protection Study [16].

The ACC/AHA Pooled Cohort Equations remain the recommended tool for quantifying 10-year ASCVD risk before initiating any PCSK9 inhibitor, including inclisiran, in patients without established ASCVD [4]. DC clinicians using the HealthRX telehealth platform can access the Pooled Cohort Equations calculator integrated into the patient intake flow.

How Does Inclisiran Compare to Other PCSK9 Inhibitors in DC?

Inclisiran, evolocumab (Repatha), and alirocumab (Praluent) all reduce LDL-C by roughly 50 to 60 percent from baseline, but they differ in administration frequency and mechanism. Evolocumab is self-injected every 2 weeks or monthly; alirocumab every 2 weeks; inclisiran twice yearly after the loading sequence [17].

For DC patients who struggle with biweekly self-injection adherence, inclisiran's twice-yearly in-office dosing may produce better real-world LDL-C control. A 2022 analysis published in the Journal of the American College of Cardiology found that adherence to biweekly PCSK9 inhibitor injections fell to roughly 55 percent at 12 months in a real-world US claims dataset, compared with near-100 percent adherence when injections are administered by a healthcare provider in a clinical setting [17].

On cost, the Novartis WAC for inclisiran ($540/month equivalent) is similar to the WAC for evolocumab 140 mg biweekly ($563/month) and alirocumab 75 mg biweekly ($498/month) before rebates [18]. Net prices after pharmaceutical rebates are substantially lower for all three agents, and the actual cost to a DC commercial payer or Medicaid program is not publicly disclosed. DC Medicaid negotiates supplemental rebates on specialty drugs, which may make one agent more cost-effective than another for the program even when WACs appear similar.

What Is the Cheapest Way to Get Leqvio in DC?

For commercially insured DC patients, the cheapest route is typically the Novartis $0 copay savings card combined with a formulary-covered plan. Patients who meet eligibility criteria pay nothing out of pocket per injection. For DC Medicaid patients, Leqvio with approved prior authorization carries no cost share under most MCO plans.

For uninsured patients or those with coverage gaps, compounded inclisiran from a licensed DC 503A pharmacy is the lowest-cost option, with some pharmacies quoting cash prices below $200 per injection. The clinical caveat is that compounded siRNA products are not FDA-reviewed for potency or purity at the batch level, and patients should request a certificate of analysis before each dispensed batch.

The GoodRx and NeedyMeds discount programs do not meaningfully reduce the cost of branded Leqvio because it is billed as a medical benefit under a J-code rather than as a retail pharmacy claim. Those programs work at the pharmacy counter for standard prescription drugs; they are not applicable to physician-administered injectables billed to medical insurance [19].

A DC patient who is Medicare-eligible, does not qualify for the manufacturer assistance program, and faces a substantial Part B cost share should ask their cardiologist to request a Medicare Part B coverage determination appeal if inclisiran is denied, citing the ACC/AHA guideline recommendation as clinical necessity support [4].

What Are the Side Effects and Safety Considerations for Leqvio?

Inclisiran's safety profile is well characterized across approximately 3,200 patient-years of exposure in the ORION clinical program. Injection-site reactions are the most common adverse event, occurring in 2.6 to 8.2 percent of patients depending on the trial and injection technique [3]. These reactions are typically mild, transient erythema or pain at the injection site, and rarely require discontinuation.

Liver enzyme elevations above three times the upper limit of normal occurred in fewer than 1 percent of inclisiran-treated patients in the ORION trials, a rate similar to placebo [3]. The FDA label does not require routine liver function monitoring during inclisiran therapy, though baseline liver function assessment is standard practice before initiating therapy with any lipid-lowering agent [1].

Because inclisiran is a siRNA compound, theoretical off-target silencing of non-PCSK9 RNA sequences was evaluated extensively in the development program. No clinically meaningful off-target organ toxicity has been identified in human trials at the 284 mg dose [3]. Animal studies at supratherapeutic doses showed reversible kidney tubular vacuolation, but this finding has not been replicated in human participants at therapeutic doses [1].

Inclisiran is classified FDA Pregnancy Category N (no human data; animal data show no harm at therapeutic doses). The drug should be used in pregnancy only if clearly needed; DC clinicians should document a pregnancy test and contraception plan for women of childbearing potential before initiating therapy, consistent with standard specialty lipid practice [1].

DC-Specific Access Points for Leqvio in 2026

Several DC health systems have established dedicated lipid clinics where inclisiran is administered as part of a cardiovascular risk reduction program. MedStar Washington Hospital Center, Georgetown University Hospital's cardiology outpatient clinic, and George Washington University Hospital's preventive cardiology service each offer in-office PCSK9 inhibitor administration with prior authorization support staff.

DC-licensed telehealth platforms including HealthRX can initiate the inclisiran prescribing process remotely, arrange the prior authorization submission, and coordinate the injection appointment at a local partner clinic. This model reduces time to first injection for patients who cannot take time off work for multiple in-person visits before therapy starts.

For patients whose primary care physician is unfamiliar with the Leqvio PA process, a referral to a DC-area preventive cardiologist or clinical lipidologist certified by the National Lipid Association can accelerate approval. The National Lipid Association maintains a clinician finder at lipid.org [13], and several NLA-certified lipidologists practice in the DC metropolitan area.

Patients should bring their most recent lipid panel (dated within 12 months), documentation of current statin dose and duration, and a list of all cardiovascular medications to their first Leqvio consultation. A fasting lipid panel showing LDL-C above 70 mg/dL on documented maximally tolerated statin therapy is the single most important document for a successful prior authorization submission in DC.